February 16, 2022
Isatuximab continues to show promise as a standard of care therapy for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitors, according to a two-year, follow-up analysis of the ICARIA-MM study However the CD38-directed monoclonal antibody may find it difficult to make its mark in the Australian setting any time soon. The study, published...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand